Tepezza Approval History
FDA Approved: Yes (First approved January 21, 2020)
Brand name: Tepezza
Generic name: teprotumumab-trbw
Dosage form: Injection
Company: Horizon Therapeutics plc
Treatment for: Thyroid Eye Disease
Tepezza (teprotumumab-trbw) is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) for the treatment of active thyroid eye disease (TED).
Development History and FDA Approval Process for Tepezza
|Jan 21, 2020|| FDA Approves Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)|
|Dec 13, 2019||FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)|
|Oct 31, 2019||Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life|
|Sep 9, 2019||Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)|
|Jul 10, 2019||Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)|
|Apr 26, 2019||New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.